Ethical and safety considerations for the use in clinical trials of new attenuated poliovirus strains.
Medical Virology, Institut Pasteur, Paris, France.
F
F
Horaud
D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods*; D004196:Disease Outbreaks; D004340:Drug Contamination; D004992:Ethics, Medical; D049673:History, 20th Century; D006801:Humans; D011044:Poland / Q000453:epidemiology; D011051:Poliomyelitis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D017955:Poliovirus / Q000145:classification / Q000235:genetics / Q000472:pathogenicity*; D011054:Poliovirus Vaccine, Inactivated / Q000009:adverse effects / Q000266:history; D011055:Poliovirus Vaccine, Oral / Q000009:adverse effects / Q000592:standards; D012449:Safety; D013539:Simian virus 40; D014774:Virulence / Q000235:genetics
D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral